1. Home
  2. VNDA vs EARN Comparison

VNDA vs EARN Comparison

Compare VNDA & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VNDA
  • EARN
  • Stock Information
  • Founded
  • VNDA 2002
  • EARN 2012
  • Country
  • VNDA United States
  • EARN United States
  • Employees
  • VNDA N/A
  • EARN N/A
  • Industry
  • VNDA Biotechnology: Pharmaceutical Preparations
  • EARN Real Estate Investment Trusts
  • Sector
  • VNDA Health Care
  • EARN Real Estate
  • Exchange
  • VNDA Nasdaq
  • EARN Nasdaq
  • Market Cap
  • VNDA 249.4M
  • EARN 223.5M
  • IPO Year
  • VNDA 2006
  • EARN 2013
  • Fundamental
  • Price
  • VNDA $5.46
  • EARN $5.17
  • Analyst Decision
  • VNDA Strong Buy
  • EARN Buy
  • Analyst Count
  • VNDA 2
  • EARN 2
  • Target Price
  • VNDA $16.50
  • EARN $6.13
  • AVG Volume (30 Days)
  • VNDA 503.6K
  • EARN 292.3K
  • Earning Date
  • VNDA 11-05-2025
  • EARN 11-11-2025
  • Dividend Yield
  • VNDA N/A
  • EARN 18.55%
  • EPS Growth
  • VNDA N/A
  • EARN N/A
  • EPS
  • VNDA N/A
  • EARN N/A
  • Revenue
  • VNDA $203,467,000.00
  • EARN $35,893,000.00
  • Revenue This Year
  • VNDA $15.45
  • EARN N/A
  • Revenue Next Year
  • VNDA $37.82
  • EARN $15.96
  • P/E Ratio
  • VNDA N/A
  • EARN N/A
  • Revenue Growth
  • VNDA 11.78
  • EARN 43.30
  • 52 Week Low
  • VNDA $3.81
  • EARN $4.33
  • 52 Week High
  • VNDA $5.59
  • EARN $7.11
  • Technical
  • Relative Strength Index (RSI)
  • VNDA 67.52
  • EARN 25.32
  • Support Level
  • VNDA $5.22
  • EARN $5.13
  • Resistance Level
  • VNDA $5.48
  • EARN $5.48
  • Average True Range (ATR)
  • VNDA 0.21
  • EARN 0.11
  • MACD
  • VNDA 0.06
  • EARN -0.05
  • Stochastic Oscillator
  • VNDA 90.31
  • EARN 0.81

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics, and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.

Share on Social Networks: